Screening for Insulin Resistance in Canada
Screen Canadian adults for insulin resistance using prediabetes/type 2 diabetes screening protocols starting at age 35, or earlier if BMI ≥25 kg/m² with additional risk factors, using A1C, fasting plasma glucose (FPG), or 2-hour oral glucose tolerance test (OGTT). 1
Who to Screen
The most recent American Diabetes Association guidelines (2023), which are widely applicable to Canadian practice, provide clear screening criteria 1:
Universal Screening
- All adults starting at age 35 years, regardless of risk factors
- Repeat every 3 years if results are normal 1
Earlier/More Frequent Screening for High-Risk Adults
Screen adults with BMI ≥25 kg/m² (or ≥23 kg/m² for Asian individuals) who have one or more of the following risk factors 1:
- First-degree relative with diabetes
- High-risk ethnicity (African American, Latino, Native American, Asian American, Pacific Islander)
- History of cardiovascular disease
- Hypertension (≥130/80 mmHg or on antihypertensive therapy)
- HDL cholesterol <0.90 mmol/L (35 mg/dL) and/or triglycerides >2.82 mmol/L (250 mg/dL)
- Polycystic ovary syndrome
- Physical inactivity
- Clinical signs of insulin resistance: severe obesity or acanthosis nigricans 1
- History of gestational diabetes (test at least every 3 years lifelong) 1
How to Screen
Laboratory Tests
Use any of these three methods 2:
- A1C ≥5.7% (39 mmol/mol) indicates prediabetes/insulin resistance
- Fasting plasma glucose 5.6-6.9 mmol/L (100-125 mg/dL) indicates impaired fasting glucose
- 2-hour OGTT glucose 7.8-11.0 mmol/L (140-199 mg/dL) indicates impaired glucose tolerance
Important caveat: While these tests identify prediabetes (a state of insulin resistance), they are the recommended screening approach rather than direct insulin resistance measurement 1, 2. Direct measurement via euglycemic clamp is not feasible in clinical practice 2.
Screening Frequency
- Normal results: Repeat every 3 years minimum 1
- Prediabetes identified (A1C 5.7-6.4%): Test yearly 1
- Higher risk profiles: Consider more frequent testing based on BMI trajectory and worsening risk factors 1
Alternative Approaches for Insulin Resistance Assessment
While not part of standard guidelines, research supports additional methods when direct assessment of insulin resistance is needed 3, 4, 5:
HOMA-IR (Homeostasis Model Assessment)
- HOMA-IR >2.5 suggests insulin resistance 6
- HOMA-IR >4.65 or >3.60 with BMI >27.5 kg/m² indicates significant insulin resistance 4
- Calculated as: (fasting insulin in μU/mL × fasting glucose in mmol/L) / 22.5
- Cut-point of HOMA-IR ≥2.29 represents the 75th percentile for insulin resistance 7
Clinical Decision Rules
A simple rule identifies insulin resistance if any of the following are met 4:
- BMI >28.9 kg/m²
- HOMA-IR >4.65
- BMI >27.5 kg/m² AND HOMA-IR >3.60
TyG-BMI Index
The triglyceride-glucose BMI index is emerging as a surrogate marker, though not yet in standard guidelines 8.
Special Populations
Children and Adolescents
Screen youth with BMI ≥85th percentile who have one or more risk factors 1:
- Start at age 10 years or onset of puberty (whichever is earlier)
- Maternal history of diabetes/gestational diabetes during gestation
- Family history of type 2 diabetes in first- or second-degree relatives
- High-risk ethnicity
- Signs of insulin resistance: acanthosis nigricans, hypertension, dyslipidemia, PCOS
- Repeat every 3 years if normal
Key Clinical Pitfalls
- Nearly half of young adults with insulin resistance are not obese 6 - don't rely solely on BMI
- Point-of-care A1C should not be used for diagnosis - requires NGSP-certified laboratory method 2
- Acanthosis nigricans is a visible clinical sign of insulin resistance that should prompt immediate screening regardless of age 1
- Visceral adiposity is more predictive than total body fat - waist circumference matters 9, 10
- The prevalence of insulin resistance among young Canadian adults is approximately 40-45% 6, making screening critical
Practical Implementation
Use the standard prediabetes screening protocol as your primary approach - it's evidence-based, guideline-supported, and identifies the clinically relevant population at risk for progression to diabetes and cardiovascular disease 1, 2. The distinction between "screening for insulin resistance" versus "screening for prediabetes" is largely semantic in clinical practice, as prediabetes represents a state of insulin resistance with measurable metabolic consequences.